These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18569930)

  • 1. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Cavdar C; Celtik A; Saglam F; Sifil A; Atila K; Celik A; Tosun P; Olmuscelik O; Bora S; Gulay H; Camsari T
    Ren Fail; 2008; 30(5):503-6. PubMed ID: 18569930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.
    Low CY; Hosseini-Moghaddam SM; Rotstein C; Renner EL; Husain S
    Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28613442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
    Nafar M; Roshan A; Pour-Reza-Gholi F; Samadian F; Ahmadpoor P; Samavat S; Abbasi MA
    Iran J Kidney Dis; 2014 May; 8(3):231-5. PubMed ID: 24878947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
    Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
    Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus disease in renal transplant recipients: a single-center experience.
    Bhadauria D; Sharma RK; Kaul A; Prasad N; Gupta A; Gupta A; Srivastava A
    Indian J Microbiol; 2012 Sep; 52(3):510-5. PubMed ID: 23997350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
    Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
    J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
    Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
    Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
    Zang S; Zhang X; Niu J; Das BB
    Clin Transplant; 2023 Jan; 37(1):e14836. PubMed ID: 36259556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infectious complications following allogeneic stem cell transplantation by using anti-thymocyte globulin-based myeloablative conditioning regimens in children with hemoglobinopathies.
    Goussetis E; Efstathiou E; Paisiou A; Avgerinou G; Zisaki K; Giamouris VJ; Peristeri I; Kitra V; Vessalas G; Gamaletsou MN; Sipsas NV; Graphakos S
    Transpl Infect Dis; 2015 Apr; 17(2):201-7. PubMed ID: 25645592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-renal transplant cytomegalovirus infection: study of risk factors.
    Kute VB; Vanikar AV; Shah PR; Gumber MR; Patel HV; Godara SM; Munjappa BC; Sainaresh VV; Engineer DP; Jain SH; Modi PR; Shah VR; Trivedi VB; Trivedi HL
    Transplant Proc; 2012 Apr; 44(3):706-9. PubMed ID: 22483473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
    Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
    Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.
    Heilman RL; Reddy KS; Mazur MJ; Moss AA; Post DJ; Petrides S; Mulligan DC
    Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
    Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
    J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipients.
    Lee YM; Kim YH; Han DJ; Park SK; Park JS; Sung H; Hong HL; Kim T; Kim SH; Choi SH; Kim YS; Woo JH; Lee SO
    Transpl Infect Dis; 2014 Jun; 16(3):397-402. PubMed ID: 24810355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.